Onconova therapeutics merger ET on Thursday, March 16, 2023NEWTOWN, Pa. (“Trawsfynydd”), a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, today announced that the companies have entered into a definitive Onconova Therapeutics, Inc. 33) by $0. The latest Onconova Therapeutics Inc (ONTX) stock news, headlines, earnings, dividends, SEC filings and insider trades to help you in your trading and investing decisions. (the “Merger”). (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended March 31, 2021 and provided a business update. reached as to the Jan 23, 2020 · About Onconova Therapeutics, Inc. You may also request a copy of these filings, at no cost, by writing or telephoning us at: Onconova Therapeutics, Inc. ET on Thursday, March 16, 2023. Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. (“Trawsfynydd”), a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, today announced that the companies have entered into a definitive Sep 22, 2021 · Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. Onconova Traws Pharma leverages broad and deep expertise in small molecule chemistry, artificial intelligence and machine learning, rational drug design & streamlined development to deliver innovative medicines. , a former publicly traded biotechnology company, from October 2014 to May 2015, where he oversaw the company’s successful merger with Tobira Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced results from its 2016 annual meeting of stockholders. Onconova Therapeutics is expected to release next earnings on 05/31/2024, with an earnings per share (EPS) estimate of $0. Michael recently served on the board of CTI Biopharma Corp. 12, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. ) 375 P h e as an t R u n Conference call begins at 4:30 p. Announced Date Apr 2, 2024 Acquisition Type Merger NEWTOWN, PA and Rockville, MD – April 2, 2024 (GLOBE NEWSWIRE) – Onconova Therapeutics, Inc. , a privately-held biotechnology company developing antivirals for Apr 1, 2024 · Onconova Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 22-3627252 (State or other jurisdiction of incorporation or organization) (I. 20 misses by $0. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to NEWTOWN, PA — In a strategic move following the acquisition of Trawsfynydd Therapeutics, Inc. 11. , Traws Pharma, Inc. (“Trawsfynydd”), a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, today announced that the companies have entered into a definitive merger agreement to The integration of Onconova and Trawsfynydd poses a significant risk to Traws Pharma, Inc. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. Marino was a partner at the global law firm Dechert LLP for 28 years, where he served as Managing Partner of the Princeton, N. Also lagging the market Tuesday are biotechnology Onconova Therapeutics, Inc. , a Best-in-Class Virology and Oncology CompanyOnconova Therapeutics, Inc. Please include, where appropriate, any conclusions Wainwright &€Co. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its fourth quarter and May 21, 2021 · NEWTOWN, Pa. THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of April 1, 2024, by and among ONCONOVA THERAPEUTICS, INC. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Onconova issued the following in the transactions: in connection with the merger, the stockholders of Traswfynydd received an aggregate of 3,549,538 shares of common stock and 10,359. 23, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Trawsfynydd), a privately-held biotechnology company developing next-generation, best-in-class antivirals Apr 4, 2024 · Newtown-based Onconova Therapeutics is joining forces in a major merger deal with drug development company, Trawsfynydd Therapeutics, writes John George for the Philadelphia Business Journal. , May 23, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. According to InvestingPro data, Onconova's market capitalization stands at a modest $21 million, reflecting the size of the company within the On January 7, 2021, Onconova Therapeutics, Inc. Food and Drug Administration (FDA) permission for a Phase 1 study to proceed under the Company’s Investigational New Drug Onconova Therapeutics, Inc. , a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), TRAWS MERGER SUB II, LLC, a Delaware limited liability company and Apr 2, 2024 · In a deal uniting two biotech companies from opposite coasts, Onconova Therapeutics and Trawsfynydd Therapeutics announced they are combining forces through an all-stock merger. , March 09, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. , Director of Corporate Development for Onconova, will present a high-level overview of the Company’s narazaciclib program at Oct 7, 2024 · In a significant development, Traws Pharma announced a merger with Onconova Therapeutics and Trawsfynydd Therapeutics, which is expected to boost Traws Pharma's financial position with an Onconova Therapeutics, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new Onconova Therapeutics and Trawsfynydd Therapeutics have entered into a definitive merger agreement to combine in an all-stock transaction. nasdaq 100. Onconova issued the following in the transactions: in connection with the merger, the stockholders of Traswfynydd Apr 2, 2024 · Onconova Therapeutics, Inc. 7% and shares of Ardelyx (ARDX) off about 15. , July 19, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develop About Onconova Therapeutics, Inc. Dec 8, 2023 · NEWTOWN, Pa. (Trawsfynydd) have recently revealed their plans to join forces in a definitive merger agreement, forming a new entity called Traws Pharma, Inc. , a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, in its merger with Onconova Therapeutics, Inc. 08, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company Apr 02 2024 10:00 BST Source: GlobeNewswire Aug 14, 2023 · The Investor Relations website contains information about Onconova Therapeutics's business for stockholders, potential investors, and financial analysts. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third Apr 1, 2024 · Onconova Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company May 15, 2024 · View differences made from one quarter to another to evaluate Onconova Therapeutics, Inc. ’s future performance, as the merger’s success hinges on achieving anticipated benefits within a set timeframe. 7 million compared to a net loss of $5. Get 60% Off The merger is expected to provide Traws Pharma with an estimated $28 million cash balance. , a privately-held biotechnology company developing antivirals for influenza, COVID and other infectious diseases, in an all-stock transaction. (“Trawsfynydd”), a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, today announced that the companies have entered into a definitive merger agreement to Apr 2, 2024 · Onconova Therapeutics, Inc. Nov 28, 2023 · Onconova Therapeutics (ONTX) reported Q3 2023 earnings per share (EPS) of-$0. com uses cookies on this site. Aug 15, 2024 · Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical milestones, put Traws on track to achieve key readouts for the clinical pipeline in H2 2024 and beyo Nov 14, 2023 · Onconova Therapeutics, Inc. According to InvestingPro data, Onconova's market capitalization stands at a modest $21 million, reflecting the size of the company within the Aug 14, 2019 · NEWTOWN, Pa. and was a Managing Director at MESA Partners, Inc. , April 19, 2023 (GLOBE Sep 11, 2024 · Onconova Therapeutics stock hits 52-week low at $0. In the same quarter last year, Onconova Therapeutics's earnings per share (EPS) was-$0. Newtown-based Onconova Therapeutics is joining forces in a major merger deal with drug development company, Trawsfynydd Therapeutics, writes John George for the Philadelphia Business Apr 2, 2024 · About the Merger and Private Financing. The Company has Apr 2, 2024 · Traws Pharma, Inc. The biopharmaceutical company reported ($0. (Nasdaq: ONTX) (“Onconova” or “the Company”), a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule Mar 15, 2023 · NEWTOWN, Pa. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first patient has been dosed in the Company’s Phase 1/2a trial evaluating narazaciclib Jul 19, 2016 · NEWTOWN, Pa. , March 23, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. NEWTOWN, Pa. 29, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) (Onconova or the Company), a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug candidate to treat Apr 2, 2024 · NEWTOWN, Pa. 13, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. , Sept. 6% in recent Tuesday trading after the company announced a merger with closely held Trawsfynydd Therapeutics in an all-stock transaction. Nov 13, 2018 · Conference Call Today at 9:00 a. Phase 1 clinical trial of ON 123300, the Company’s proprietary Feb 17, 2021 · What happened. Eastern Time. 29 by 20. 69%. , May 21, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. office. 2, 2024 - Onconova Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel products candidates to treat cancer. What is the stock ticker? ONTX Jan 16, 2025 · ONCONOVA THERAPEUTICS INC. 33 Open in App. According to InvestingPro data, Onconova's market capitalization stands at a modest $21 million, reflecting the size of the company within the Dec 26, 2024 · Onconova Therapeutics, Inc. 2% on the day. About Onconova Therapeutics, Inc. Read. We note that Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today provided a corporate update and reported financial results for the second quarter ended June 30, 2019. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company April 02, 2024 07:00 ET Apr 2, 2024 · Onconova Therapeutics, Inc. So what. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. May 23, 2024 · Differentiated resistance profile positions Traws’ program as a potential class leader. ET today. Eastern time today. (Nasdaq: TRAW) has awarded equity grants to five Onconova is focused on discovering and developing novel products for patients with cancer. ) 375 Pheasant Run Newtown, PA 18940 (267) 759-3680 (Address, including zip code, and telephone number, including area code, of registrant’s principal Mar 16, 2023 · Conference call and live webcast at 4:30 p. Onconova holds the distinction of being the oldest biotechnology firm in the region, yet it has not successfully brought a product to market approval. 06M misses by $0. ’s future performance, as the merger’s success hinges on achieving anticipated benefits within a set Apr 2, 2024 · On April 02, 2024 Onconova Therapeutics, Inc. 21, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (collectively, the “Investors”) for the sale by the Company directly to the Investors of an aggregate of 19,551,124 shares of the Company’s common stock Oct 29, 2018 · NEWTOWN, Pa. ), a publicly held biopharmaceutical company, since July 2015. (NASDAQ: ONTX) (“Onconova”), and Trawsfynydd Therapeutics, Inc. , About the Merger and Private Financing. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Onconova Therapeutics, Inc. 22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company 02 avr. S. ("Trawsfynydd") in connection with the acquisition (the "Merger") by Traws Pharma, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. ET today NEWTOWN, Pa. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. Apr 2, 2024 · Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; travaltrelvir, a protease inhibitor for COVID19; and narazaciclib, a next generation CDK4/6 inhibitor for low NEWTOWN, Pa. , March 11, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (E xa c t na m e of re gi s t ra nt a s s pe c i fi e d i n c ha rt e r) D e l aw are (S t a t e or ot he r j uri s di c t i on of i nc orpora t i on or orga ni z a t i on) 22-3627252 (I. , April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced presentation of a poster at the annual International Conference on Apr 2, 2024 · Newtown’s Onconova Therapeutics Secures $14 Million and New CEO in Merger with Trawsfynydd April 3, 2024 | msn. by Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients Apr 2, 2024 · Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to ad Apr 2, 2024 · Onconova Therapeutics, Inc. . (“Trawsfynydd”), a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, today announced Sep 18, 2024 · Onconova Therapeutics Hits 52-Week Low of $0. Sep 30, 2024 · These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Traws’ clinical trials, collaborations, merger integration, market conditions and those discussed under the heading “Risk Factors” in Traws’ filings with the U. Onconova issued the following in the transactions: in connection with the merger, the stockholders of Traswfynydd received an aggregate of 3,549,538 shares Sep 20, 2024 · “The Company has taken a very strategic approach to building and expanding its pipeline, starting with the April 2024 merger agreement with Trawsfynydd, one of the “Loch Companies” founded by the innovative i2020 Accelerator, supported by Torrey Pines Investments and Orbimed. (ONTX) announced Tuesday that it has acquired Trawsfynydd Therapeutics, Inc. ("Trawsfynydd"), a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, reported that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the "Merger") (Press release Onconova Therapeutics (NASDAQ:ONTX) traded lower on Tuesday after the company acquired privately-held biotech Trawsfynydd Therapeutics, in an all-stock transaction following a definitive merger Nov 14, 2023 · NEWTOWN, Pa. E m pl oye r Ide nt i fi c a t i on N o. The Company has proprietary targeted anti-cancer Jun 7, 2023 · Onconova Therapeutics, Inc. com Onconova Acquires Trawsfynydd To Form Traws Pharma Onconova Therapeutics’s most recent deal was a Reverse Merger with Traws Pharma for . This merger is expected to provide Traws Pharma Onconova Therapeutics, Inc. The Company has proprietary targeted anti- Apr 2, 2024 · As Onconova Therapeutics transitions into Traws Pharma following its merger with Trawsfynydd Therapeutics, investors are closely monitoring the financial health and market performance of the company. (f/k/a Onconova Therapeutics, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. federal income tax purposes. to render an opinion to the Onconova board of directors as to the fairness, from a financial point of view, to Onconova of the exchange ratio pursuant to the merger agreement. Apr 2, 2024 · Onconova Therapeutics (NASDAQ:ONTX) traded lower on Tuesday after the company acquired privately-held biotech Trawsfynydd Therapeutics, in an all-stock transaction following a definitive merger Apr 2, 2024 · The merger between Onconova Therapeutics and Trawsfynydd Therapeutics to form Traws Pharma is a strategic move that is likely to have a considerable impact on the biotechnology market, especially in the infectious disease and oncology sectors. (NASDAQ: ONTX), ( Onconova ), a clinical-stage Nov 7, 2022 · Company to host conference call and webcast at 4:30 p. , March 16, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. ) 375 P h e as an t R u n , N e w tow n , PA 18940 (Address of principal executive offices) (Zip Code) Apr 2, 2024 · Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey Pines; Funding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; travaltrelvir, a protease inhibitor for COVID19; and narazaciclib, a next generation CDK4/6 inhibitor for low 4 days ago · Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023. 28, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. S . (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the enrollment of the first patient in Japan by SymBio Pharmaceuticals in the global Phase 3 INSPIRE trial, investigating IV rigosertib as a treatment for higher-risk “I am pleased to announce the combination of Onconova and Trawsfynydd at this important time, as Trawsfynydd readies to initiate Phase 2 studies in H2 2024 for its lead antiviral programs for influenza and COVID19, supported by advisors with unparalleled expertise in viral disease, and Onconova is preparing to finalize the recommended Phase 2 Apr 2, 2024 · (2024-04-02 | NDAQ:TRAW) Onconova Therapeutics, Inc. Aktie Heute aktuelle News ⇒ Jetzt informieren! Congratulations to our client Onconova Therapeutics on entering into a definitive merger agreement with Trawsfynydd Therapeutics to form Traws Pharma, “a best-in-class virology and oncology May 11, 2023 · Prior data provide clinical proof-of-concept for narazaciclib’s mechanism of action in endometrial cancer Preliminary data from trial’s Phase 1 portion expected in 4Q 2023 NEWTOWN, Pa. Apr 2, 2024 · NEWTOWN, Pa. (NasdaqCM:ONTX) has entered into a definitive merger agreement to acquire Trawsfynydd Therapeutics, Inc. euro stoxx 50. (NASDAQ: NASDAQ: ONTX) and Trawsfynydd Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel Apr 2, 2024 · Onconova Therapeutics, Inc. (the “Second Merger” and together with the First Merger, the “Merger”). R. com. Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. Contact © 2016 - 2025 Oncternal Therapeutics. Apr 2, 2024 · Onconova Therapeutics, Inc. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer May 21, 2021 · Earlier this week, Onconova Therapeutics released its earnings for the first quarter of 2021 and posted a net loss of $4. , May 11, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. m. Conference call and live webcast at 4:30 p. 23, beating estimates of -$0. , a Delaware corporation (“Parent”), TRAWS MERGER SUB I, INC. 27 Dec 2024, 17:15 UTC. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that Dr. The Company has Table of Contents . 1 million in the same period in 2020. (NASDAQ:ONTX) ("Onconova"), and Trawsfynydd Therapeutics, Inc. THE COMPANIES Explanation of Responses: 1. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company Stockhouse. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. May 20, 2021 · About Onconova Therapeutics, Inc. 's financial trajectory Sample 10-K Year-over-Year (YoY) Comparison Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova" or the "Company"), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced it filed a registration statement amendment on Form S-1/A with the Securities and Exchange Commission (the "SEC") for a previously Apr 2, 2024 · -- Onconova Therapeutics shares fell 4. Prior to July 2015, Mr. The Merger is intended to qualify as a tax-free reorganization for U. D. This significant drop reflects a troubling period for the biopharmaceutical company that dedicates its efforts toward discovering and developing innovative treatments for cancer. This Marino has served as a member of the board of directions of Traws Pharma, Inc. (E xa c t na m e of R e gi s t ra nt a s s pe c i fi e d i n i t s c ha rt e r) D e l aw are 001-36020 22-3627252 (S t a t e or O t he r J uri s di c t i on of Inc orpora t i on or O rga ni z a t i on) (C om m i s s i on F i l e N um be r) (I. , 375 Pheasant Run, Newtown, PA 18940, (267) 759-3680. Sep 17, 2024 · These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Traws’ clinical trials, collaborations, merger integration, market conditions and those discussed under the heading “Risk Factors” in Traws’ filings with the Securities and Exchange Commission. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced receipt of U. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for patients with cancer, announces financial results for the twelve months ended December 31, 2020 and provides a business update. 375 Pheasant Run Newtown, PA 18940 (267) 759-3680 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Ramesh Ku Nov 20, 2024 · In a significant corporate move, Traws Pharma announced a merger with Onconova Therapeutics and Trawsfynydd Therapeutics, expected to bolster its financial position with an estimated cash balance Onconova Therapeutics, Inc. 01, revenue of $0. (“Trawsfynydd”), a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, today announced BACK TO HOME. 32. , a privately-held biotechnology company developing antivirals for influenza Apr 2, 2024 · --Onconova Therapeutics, Inc. 29%) surged 23. Nov 16, 2024 · The integration of Onconova and Trawsfynydd poses a significant risk to Traws Pharma, Inc. ) 375 P h e as an t R u n N e w tow n , PA 18940 (267) 759-3680 Onconova Therapeutics Inc Chart. All rights reserved Jan 17, 2018 · About Onconova Therapeutics, Inc. , June 29, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. have announced the completion of their merger, forming a new entity Apr 2, 2024 · (RTTNews) - Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the twelve months ended December 31, 2022, and provided a business Apr 2, 2024 · Onconova Therapeutics Onconova Therapeutics is a biopharmaceutical company developing small molecule drug candidates for the treatment of cancer. - Onconova Therapeutics, Inc. DJ. (NASDAQ: ONTX) (Onconova), and Trawsfynydd Therapeutics, Inc. retained H. (NASDAQ: ONTX), (“Onconova Sep 25, 2018 · Reverse split intended primarily to increase the per share bid price of Onconova's common stock and satisfy the Nasdaq Capital Market continued listing requirement; NEWTOWN, Pa. 26. C. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first patient has been dosed in the U. Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile. (NASDAQ: ONTX) and Trawsfynydd Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended Mar 9, 2023 · Company to host conference call and webcast at 4:30 p. Orrick advised Onconova Therapeutics, which acquired 100% of Trawsfynydd’s outstanding equity interests. , (formerly Onconova Therapeutics, Inc. The combined company is known as Traws Pharma, Inc. (NASDAQ: TRAW) stock has recently plummeted to a new 52-week low, reaching a price of $0. (Exact name of registrant as specified in its charter) D e l aw are 22-3627252 (State or other jurisdiction of (I. 32 Onconova Therapeutics Inc. Prior to Forest, Michael served as Vice President Corporate Development at Onconova Therapeutics, Inc. R . Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent Sep 25, 2018 · Onconova Therapeutics, Inc. , Oct. Company Name Sep 23, 2021 · NEWTOWN, Pa. ("Trawsfynydd"), a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, today announced that the NEWTOWN, Pa. 0916 shares of newly issued Series C non-voting convertible Apr 2, 2024 · Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey Pines Funding expected to advance Jan 4, 2018 · About Onconova Therapeutics, Inc. , May 20, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. | Onconova Therapeutics, Inc. (NASDAQ: ONTX) is a clinical-stage biopharmaceutical company focused on 4. 25, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. Under the terms of the Merger Agreement, upon the consummation of the Merger on April 1, 2024 (the “Closing”), in exchange for the outstanding shares Onconova Therapeutics (NASDAQ:ONTX) traded lower on Tuesday after the company acquired privately-held biotech Trawsfynydd Therapeutics, in an all-stock transaction following a definitive merger Michael was President & COO from December 2013 to October 2014 and President, CEO and a member of the board of directors of Regado Biosciences, Inc. (NASDAQ:ONTX) posted its quarterly earnings data on Thursday, November, 11th. , the "Company") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Onconova Therapeutics, Inc. Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent May 11, 2023 · NEWTOWN, Pa. (NasdaqCM:ONTX) entered into a definitive merger agreement to acquire Trawsfynydd Therapeutics, Inc. Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel drugs to treat cancer. rigosertib from Onconova in July 2011 for Japan and Korea. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preclinical data highlighting narazaciclib’s multi-kinase profile, broad Onconova Therapeutics’ Strategic Acquisition and Corporate Sep 28, 2021 · NEWTOWN, Pa. 2024 07h00 HE | Source . Apr 2, 2024 · In connection with the Merger, Traws announced that it will raise $14 million in a committed private placement financing by OrbiMed and Torrey Pines, expected to close on April 3, 2024. , May 17, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. Employer incorporation or organization) Identification No. The newly created entity, dubbed Traws Pharma, will have a deep pipeline spanning virology and oncology when it begins trading on the Nasdaq as “TRAW” this Wednesday. , March 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Clinical trials with the Company's compound Sep 26, 2024 · Traws Pharma has also announced a merger with Onconova Therapeutics and Trawsfynydd Therapeutics, aiming to advance potential assets in viral diseases and cancer treatment development. , March 26, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. Mar 23, 2022 · NEWTOWN, Pa. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Apr 2, 2024 · As Onconova Therapeutics transitions into Traws Pharma following its merger with Trawsfynydd Therapeutics, investors are closely monitoring the financial health and market performance of the company. in 2015. The merger 4 days ago · Onconova Therapeutics, Inc. 02M SA News Wed, May 11, 2022. , Nov. (ISIN: US68232V3069) Realtime-Kurs der ONCONOVA THERAPEUTICS INC. 14, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today May 22, 2024 · Who is Onconova Therapeutics. , a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction. announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Adar Makovski Silverstein, Ph. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug candidate to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided a corporate update and announced financial results Dec 21, 2020 · NEWTOWN, Pa. Oct 12, 2023 · Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need. , and Trawsfynydd Therapeutics, Inc. J. Securities and Exchange Apr 2, 2024 · (RTTNews) - Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Mar 9, 2023 · Company to host conference call and webcast at 4:30 p. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). and ROCKVILLE, Md. for approximately $110 million on April 1, 2024. Employer Identification No. , a publicly traded biopharmaceutical company which was acquired by SOBI AB in 2023, as well as the boards Data further characterize narazaciclib’s mechanism of action and show its anti-cancer activity comparing favorably to that of FDA-approved CDK 4/6 inhibitorsNEWTOWN, Pa. (Nasdaq: ONTX) (“Onconova” or “the Company”), a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug candidate Jun 17, 2021 · The Investor Relations website contains information about Onconova Therapeutics's business for stockholders, potential investors, and financial analysts. Ramesh Kumar, CEO, will be meeting with potential Investors and Business Development partners at the 2018 Bio Jun 29, 2016 · NEWTOWN, Pa. , Aug. on April 2, 2024. Jan 15, 2025 · Onconova slips after all-stock merger with Trawsfynydd SA News Tue, Onconova Therapeutics GAAP EPS of -$0. 8% on Wednesday, bringing the biopharmaceutical company's year-to-date gains to an impressive 245%. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results and provided an update on recent pipeline Helping drag down the group were shares of Onconova Therapeutics (ONTX), off about 34. 333-221684 Apr 2, 2024 · As Onconova Therapeutics transitions into Traws Pharma following its merger with Trawsfynydd Therapeutics, investors are closely monitoring the financial health and market performance of the company. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important Onconova Therapeutics, Inc. , a venture capital firm. ftse-100 Sep 18, 2024 · Traws Pharma announced a merger with Onconova Therapeutics and Trawsfynydd Therapeutics, aiming to develop treatments for viral diseases and cancer. Eastern Time on Monday, November 14, 2022. Onconova Therapeutics is a clinical- stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. Wainwright &€Co. However, the company Apr 2, 2024 · NEWTOWN, Pa. Common Stock (ONTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Amedisys Stock Gains as Merger Extension Raises Hope for UnitedHealth Deal -- Barrons. The deal was made on 02-Apr-2024. Onconova issued the following in the transactions: in connection Apr 2, 2024 · Onconova Therapeutics, Inc. Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update March 16, 2023 Conference call and live webcast at 4:30 p. Shares of Onconova Therapeutics (ONTX 0. , Dec. , April 02, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. , May 11 May 20, 2016 · NEWTOWN, Pa. has entered into a definitive merger agreement to acquire Trawsfynydd Therapeutics, Inc. Apr 2, 2024 · SAN DIEGO – Snell & Wilmer represented Maryland-based client Trawsfynydd Therapeutics, Inc. Apr 2, 2024 · Read Press Release for Onconova Therapeutics (ONTX) published on Apr. xwwwo ans zatcovl mfivym jhn fjofqmw itealv ztbaai asi svyl